BioGaia, Nestle infant formula
This article was originally published in The Tan Sheet
BioGaia will provide Lactobacillus reuteri probiotic to Nestle Nutrition for use in infant formula products, the Stockholm, Sweden-based biotechnology firm says Aug. 21. BioGaia President Peter Rothschild credits the firm's probiotic safety data as "a strong factor in facilitating the agreement with Nestle," which has an existing partnership with BioGaia in the health care nutrition area. The infant formula deal will cover all world markets, excluding Korea and Japan, with an initial product launch planned for 2009
You may also be interested in...
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.